Crispr Therapeutics Financial Results
CRISPR Therapeutics reported Q3 2026 financial results, highlighted by $99 million in CASGEVY revenue, representing 30% quarter-over-quarter growth. The company also announced FDA RMAT designations for CTX310 and the appointments of a new Chief Technical Officer and Chief Financial Officer.
- Term
- Q3 2026
“The third quarter marked meaningful progress for CRISPR Therapeutics. CASGEVY is reaching more patients, including younger children following new approvals in the U.K. and the Middle East, and the FDA’s RMAT designations for CTX310 underscore its potential to address significant unmet needs in cardiovascular disease. With new clinical data from CTX310 and zugo-cel in the coming weeks and enrollment complete in our Phase 2 trial of CTX611, we are entering a pivotal period for our pipeline.”
Samarth Kulkarni, Ph.D., Chairman and Chief Executive Officer